WEREWOLF THERAPEUTICS, INC. Net Change in Cash
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Net Change in Cash of -$35.96 million for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$10.60M.
- WEREWOLF THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$18.95M, a 490.60% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $4.85M, a 87.42% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $38.56M.
- WEREWOLF THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $25.05M.
- WEREWOLF THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$28.30M, a 142.85% decline from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was $66.05M, a 11.54% decline from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was $74.67M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$35.96M S-4 · filed 2026-09-22 | |||
| 2026-03-31 | -$10.60M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$54.26M S-4 · filed 2026-09-22 | |||
| 2025-09-30 | -$45.61M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | -$33.72M S-4 · filed 2026-09-22 | |||
| 2025-03-31 | -$18.95M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$43.36M S-4 · filed 2026-09-22 | |||
| 2024-09-30 | -$31.53M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | -$19.06M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $4.85M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $25.05M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $20.76M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $28.15M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $38.56M 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | -$28.30M 10-K · filed 2024-03-07 | |||
| 2022-09-30 | -$17.17M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$11.82M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$13.82M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $66.05M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $78.96M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $91.75M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$7.88M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $74.67M 10-K · filed 2022-03-24 | |||
| 2020-09-30 | $8.81M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $13.89M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$3.85M 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |